Lymphatic System Health in Alzheimer's Disease
Alzheimer Disease
About this trial
This is an interventional treatment trial for Alzheimer Disease focused on measuring dexmedetomidine, lymphatic system
Eligibility Criteria
Inclusion Criteria:
- In order for a subject to be considered for this study, the subject must be willing to comply with the study protocol. They must be between 18 and 90 years old. They must complete neurocognitive testing to assess cognitive impairment (QDRS and RBANS).
Exclusion Criteria:
- Advanced stages of any terminal illness or any active cancer that requires chemotherapy
- Hepatic impairment
- Significant cytopenia
- Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis
- Women who are pregnant, may become pregnant, or are breastfeeding
- Any counter indications to dexmedetomidine
- Subjects unable to give informed consent or in vulnerable categories, such as prisoners
Sites / Locations
- Westwood Open MRI
- Neurological Associates of West Los Angeles
Arms of the Study
Arm 1
Experimental
Dexmedetomidine
All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.